Top

Journal of Endocrinological Investigation

Published in:

Open Access 01-12-2015 | Review

Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings

Authors: M. A. Angulo, M. G. Butler, M. E. Cataletto

Published in: Journal of Endocrinological Investigation | Issue 12/2015

Abstract

Introduction

Prader-Willi syndrome (PWS) is a multisystemic complex genetic disorder caused by lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 region. There are three main genetic subtypes in PWS: paternal 15q11-q13 deletion (65–75 % of cases), maternal uniparental disomy 15 (20–30 % of cases), and imprinting defect (1–3 %). DNA methylation analysis is the only technique that will diagnose PWS in all three molecular genetic classes and differentiate PWS from Angelman syndrome. Clinical manifestations change with age with hypotonia and a poor suck resulting in failure to thrive during infancy. As the individual ages, other features such as short stature, food seeking with excessive weight gain, developmental delay, cognitive disability and behavioral problems become evident. The phenotype is likely due to hypothalamic dysfunction, which is responsible for hyperphagia, temperature instability, high pain threshold, hypersomnia and multiple endocrine abnormalities including growth hormone and thyroid-stimulating hormone deficiencies, hypogonadism and central adrenal insufficiency. Obesity and its complications are the major causes of morbidity and mortality in PWS.

Methods

An extensive review of the literature was performed and interpreted within the context of clinical practice and frequently asked questions from referring physicians and families to include the current status of the cause and diagnosis of the clinical, genetics and endocrine findings in PWS.

Conclusions

Updated information regarding the early diagnosis and management of individuals with Prader-Willi syndrome is important for all physicians and will be helpful in anticipating and managing or modifying complications associated with this rare obesity-related disorder.

Prader A, Labhart A, Willi H (1956) Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im neugeborenenalter. Schweiz Med Wochenschr 86:1260–1261

Bittel DC, Butler MG (2005) Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev Mol Med 7(14):1–20PubMedCrossRef

Butler MG, Lee PDK, Whitman BY (2006) Management of Prader-Willi Syndrome. Springer, New YorkCrossRef

Butler MG (2011) Prader-Willi syndrome: obesity due to genomic imprinting. Curr Genomics 12:204–215PubMedCentralPubMedCrossRef

Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14(1):10–26PubMedCrossRef

Aycan Z, Bas VN (2014) Prader-Willi syndrome and growth hormone deficiency. J Clin Res Pediatr Endocrinol 6(2):62–67PubMedCentralPubMedCrossRef

Buiting K (2010) Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 154C:365–376PubMedCrossRef

Williams CA, Driscoll DJ, Dagli AI (2010) Clinical and genetic aspects of Angelman syndrome. Genet Med 12(7):385–395PubMedCrossRef

Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M (1989) Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 342(6247):281–285PubMedCrossRef

10.

Nicholls RD, Knepper JL (2001) Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Ann Rev Genomics Hum Genet 2:153–175CrossRef

11.

Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, El-Maarri O, Horsthemke B (2003) Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect. Am J Hum Genet 72(3):571–577PubMedCentralPubMedCrossRef

12.

Butler MG, Thompson T (2000) Prader-Willi syndrome: clinical and genetic finding. Endocrinology 10:3S–16SCrossRef

13.

Butler MG (1990) Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 35(3):319–332PubMedCrossRef

14.

Sun Y, Nicholls RD, Butler MG, Saitoh S, Hainline BE, Palmer CG (1996) Breakage in the SNRPN locus in a balanced 46, XY, t(15;19) Prader-Willi syndrome patient. Hum Mol Genet 5(4):517–524PubMedCrossRef

15.

Butler MG, Christian SL, Kubota T, Ledbetter DH (1996) A 5-year-old white girl with Prader-Willi syndrome and a submicroscopic deletion of chromosome 15q11q13. Am J Med Genet 65(2):137–141PubMedCrossRef

16.

Kim SJ, Miller JL, Kuipers PJ, German JR, Beaudet AL, Sahoo T, Driscoll DJ (2012) Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes. Eur J Hum Genet 20(3):283–290PubMedCentralPubMedCrossRef

17.

Rocha CF, Paiva CL (2014) Prader-Willi-like phenotypes: a systematic review of their chromosomal abnormalities. Genet Mol Res 1:2290–2298CrossRef

18.

Butler MG (2009) Genomic imprinting disorders in humans: a mini-review. J Assist Reprod Genet 26(9–10):477–486PubMedCentralPubMedCrossRef

19.

Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F (1993) Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91(2):398–402PubMed

20.

Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB (2001) The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108(5):E92PubMedCrossRef

21.

Bittel DC, Kibiryeva N, Butler MG (2007) Methylation-specific multiplex ligation-dependent probe amplification analysis of subjects with chromosome 15 abnormalities. Genet Test 11(4):467–475PubMedCrossRef

22.

Henkhaus RS, Kim SJ, Kimonis VE, Gold JA, Dykens EM, Driscoll DJ, Butler MG (2012) Methylation-specific multiplex ligation-dependent probe amplification and identification of deletion genetic subtypes in Prader-Willi syndrome. Genet Test Mol Biomarkers 16(3):178–186PubMedCentralPubMedCrossRef

23.

Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ (2011) Nutritional phases in Prader-Willi syndrome. Am J Med Genet A 155(5):1040–1049CrossRef

24.

Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS (2002) Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 8(7):643–644PubMedCrossRef

25.

Del Parigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA (2002) High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 87:5461–5464CrossRef

26.

Tan TM-M, Vanderpump M, Khoo B, Patterson M, Ghatei MA, Goldstone AP (2004) Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 89(8):4162–4165PubMedCrossRef

27.

De Waele K, Ishkanian SL, Bogarin R, Miranda CA, Ghatei MA, Bloom SR, Pacaud D, Chanoine JP (2008) Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol 159(4):381–388PubMedCrossRef

28.

Kweh FA, Miller JL, Sulsona CR, Wasserfall C, Atkinson M, Shuster JJ, Goldstone AP, Driscoll DJ (2015) Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A 167(1):69–79CrossRef

29.

Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T (2002) Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med and Child Neurol 44(4):248–255CrossRef

30.

Haqq AM, Muehlbauer MJ, Newgard CB, Grambow S, Freemark M (2011) The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab 96:E225–E232PubMedCentralPubMedCrossRef

31.

Diene G, Mimoun E, Feigerlova E et al (2010) French Reference Centre for PWS. Endocrine disorders in children with Prader-Willi syndrome–data from 142 children of the French database. Horm Res Paediatr 74:121–128PubMedCrossRef

32.

Waterland RA, Jirtle RL (2004) Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 20(1):63–68PubMedCrossRef

33.

Bittel DC, Kibiryeva N, Talebizadeh Z, Butler MG (2003) Microarray analysis of gene/transcript expression in Prader-Willi syndrome: deletion versus UPD. J Med Genet 40(8):568–574PubMedCentralPubMedCrossRef

34.

Bittel DC, Kibiryeva N, Talebizadeh Z, Driscoll DJ, Butler MG (2005) Microarray analysis of gene/transcript expression in Angelman syndrome: deletion versus UPD. Genomics 85(1):85–91PubMedCrossRef

35.

Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, Garnica A, Cheung SW, Beaudet AL (2008) Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 40(6):719–721PubMedCentralPubMedCrossRef

36.

de Smith AJ, Purmann C, Walters RG, Ellis RJ, Holder SE, Van Haelst MM, Brady AF, Fairbrother UL, Dattani M, Keogh JM, Henning E, Yeo GS, O’Rahilly S, Froguel P, Farooqi IS, Blakemore AI (2009) A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 18(17):3257–3265PubMedCentralPubMedCrossRef

37.

Bieth E, Eddiry S, Gaston V, Lorenzini F, Buffet A, Conte Auriol F, Molinas C, Cailley D, Rooryck C, Arveiler B, Cavaille J, Salles JP, Tauber M (2015) Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi syndrome. Eur J Hum Genet 23(2):252–255PubMedCrossRef

38.

Kishore S, Stamm S (2006) The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 311(5758):230–232PubMedCrossRef

39.

Schaaf CP, Gonzalez-Garay ML, Xia F, Potocki L, Gripp KW, Zhang B, Peters BA, McElwain MA, Drmanac R, Beaudet AL, Caskey CT, Yang Y (2013) Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nat Genet 45(11):1405–1408PubMedCrossRef

40.

Macedo DB, Abreu AP, Reis AC, Montenegro LR, Dauber A, Beneduzzi D, Cukier P, Silveira LF, Teles MG, Carroll RS, Junior GG, Filho GG, Gucev Z, Arnhold IJ, de Castro M, Moreira AC, Martinelli CE Jr, Hirschhorn JN, Mendonca BB, Brito VN, Antonini SR, Kaiser UB, Latronico AC (2014) Central precocious puberty that appears to be sporadic caused by paternally inherited mutations in the imprinted gene makorin ring finger 3. J Clin Endocrinol Metab 99(6):E1097–E1103PubMedCentralPubMedCrossRef

41.

Buiting K, Nazlican H, Galetzka D, Wawrzik M, Gross S, Horsthemke B (2007) C15orf2 and a novel noncoding transcript from the Prader-Willi/Angelman syndrome region show monoallelic expression in fetal brain. Genomics 89(5):588–595PubMedCrossRef

42.

Chai JH, Locke DP, Greally JM, Knoll JH, Ohta T, Dunai J, Yavor A, Eichler EE, Nicholls RD (2003) Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet 73(4):898–925PubMedCentralPubMedCrossRef

43.

Butler MG (1989) Hypopigmentation: a common feature of Prader-Labhart-Willi syndrome. Am J Hum Genet 45(1):140–146PubMedCentralPubMed

44.

Butler MG, Fischer W, Kibiryeva N, Bittel DC (2008) Array comparative genomic hybridization (aCGH) analysis in Prader-Willi syndrome. Am J Med Genet Part A 146A(7):854–860PubMedCrossRef

45.

Bittel DC, Kibiryeva N, Butler MG (2006) Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi syndrome. Pediatrics 118(4):e1276–e1283PubMedCrossRef

46.

Svenstrup K, Moller RS, Christensen J, Budtz-Jorgensen E, Gilling M, Nielsen JE (2011) NIPA1 mutation in complex hereditary spastic paraplegia with epilepsy. Eur J Neurol 18(9):1197–1199PubMedCrossRef

47.

Burnside RD, Pasion R, Mikhail FM, Carroll AJ, Robin NH, Youngs EL, Gadi IK, Keitges E, Jaswaney VL, Papenhausen PR, Potluri VR, Risheg H, Rush B, Smith JL, Schwartz S, Tepperberg JH, Butler MG (2011) Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay. Hum Genet 130(4):517–528PubMedCrossRef

48.

Jerkovich AM, Butler MG (2014) Further phenotypic expansion of 15q11.2 BP1-BP2 microdeletion (Burnside-Butler) syndrome. J Ped Genet 3(1):41–44

49.

Cox DM, Butler MG (2015) The 15q11.2 BP1-BP2 microdeletion syndrome: a review. Int J Mol Sci 16(2):4068–4082PubMedCentralPubMedCrossRef

50.

Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T (2004) Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 113:565–573PubMedCrossRef

51.

Zarcone J, Napolitano D, Peterson C, Breidbord J, Ferraioli S, Caruso-Anderson M, Holsen L, Butler MG, Thompson T (2007) The relationship between compulsive behaviour and academic achievement across the three genetic subtypes of Prader-Willi syndrome. J Intellect Disabil Res 51:478–487PubMedCrossRef

52.

Cassidy SB, Lai LW, Erickson RP, Magnuson L, Thomas E, Gendron R, Herrmann J (1992) Trisomy 15 with loss of the paternal 15 as a cause of Prader-Willi syndrome due to maternal disomy. Am J Hum Genet 51:701–708PubMedCentralPubMed

53.

Butler MG, Sturich J, Myers SE, Gold JA, Kimonis V, Driscoll DJ (2009) Is gestation in Prader-Willi syndrome affected by the genetic subtype? J Assist Reproduct Genet 26(8):461–466CrossRef

54.

Newkirk HL, Bittel DC, Butler MG (2008) Analysis of the Prader-Willi syndrome chromosome region using quantitative microsphere hybridization (QMH) array. Am J Med Genet Part A 146A(18):2346–2354PubMedCrossRef

55.

Beebe D (2006) Neurobehavioral morbidity associated with disordered breathing during sleep in children: a comprehensive review. Sleep 29(9):1115–1134PubMed

56.

Maas AP, Sinnema M, Didden R, Maaskant MA, Smits MG, Schrander-Stumpel CT, Curfs LM (2010) Sleep disturbances and behavioral problems in adults with PWS. J Intellect Disabil Res 54:906–917PubMedCrossRef

57.

Sedky K, Bennett DS, Pumariega A (2014) Prader-Willi syndrome and obstructive sleep apnea: co-occurrence in the pediatric population. J Clin Sleep Med 10(4):403–409PubMedCentralPubMed

58.

Bruni O, Verrillo E, Novellia L, Ferric R (2010) Prader-Willi Syndrome: sorting out the relationships between obesity, hypersomnia and sleep apnea. Curr Opin Pulm Med 16:568–573PubMedCrossRef

59.

Weselake SV, Foulds JL, Couch R et al (2014) Prader-Willi syndrome, excessive daytime sleepiness and narcoleptic symptoms: a case report. J Med Case Rep 8:127PubMedCentralPubMedCrossRef

60.

Nishino S, Kanbayashi T (2005) Symptomatic narcolepsy, cataplexy and hypersomnia and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9(4):269–310PubMedCrossRef

61.

Arii J, Kanbayashi T, Tanabe Y et al (2004) CSF hypocretin 1 levels in childhood narcolepsy and neurologic disorders. Neurology 63(12):2440–2442PubMedCrossRef

62.

Bittel DC, Kibiryeva N, Sell SM, Strong TV, Butler MG (2007) Whole genome microarray analysis of gene expression in Prader-Willi syndrome. Am J Med Genet 143A(5):430–442PubMedCrossRef

63.

Fronczek R, Lammers J, Balesar R et al (2005) The number of hypothalamic hypocretin neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab 90:5466–5470PubMedCrossRef

64.

Maas AP, Didden R, Bouts L, Smits MG, Curfs LM (2009) Scatter plot analysis of excessive daytime sleepiness and severe disruptive behavior in adults with PWS: a pilot study. Res Dev Disabil 30:529–537PubMedCrossRef

65.

Lindgren AC, Hellstrom LG, Ritzen EM, Milerad J (1999) Growth hormone treatment increases CO2 response, ventilation and central inspiratory drive in children with PWS. Eur J Pediatr 158:936–940PubMedCrossRef

66.

Katz-Solomon M, Lindgren AC, Cohen G (2012) The effect of growth hormone on sleep related cardiopulmonary control in PWS. Acta Paediatr 101(6):643–648CrossRef

67.

Al-Saleh S, Al-Naimi A, Hamilton J et al (2013) Longitudinal evaluation of sleep disordered breathing in children with PWS during 2 years of growth hormone therapy. J Pediatr 162:263–268PubMedCrossRef

68.

Berini J, Spica-Russotto V, Castelnuevo P et al (2013) Growth hormone therapy and respiratory disorders: long term follow-up in PWS children. J Clin Endocrinol Metab 98(9):E1516–E1523PubMedCrossRef

69.

Katz ES, Marcus CL (2014) Diagnosis of obstructive sleep Apnea syndrome in infants and children. In: Sheldon SH, Ferber R, Kryger M, Gozal D (eds) Principles and practice of pediatric sleep medicine, 2nd edn. Elsevier, New York, pp 321–322

70.

Whitman BY, Myers SE (2013) Prader-Willi syndrome and growth hormone therapy: take a deep breath and weigh the data. J Peds 162(2):224–226CrossRef

71.

Bhattacharjee R, Kheirandish-Gozal LK, Spruyt K et al (2010) Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children. Am J Respir Crit Care Med 182:676–683PubMedCrossRef

72.

Meyer SL, Splaingard M, Repaske DR et al (2012) Outcomes of adenotonsillectomy in patients with Prader-Willi syndrome. Arch Otolaryngol Head Neck Surg 138(11):1047–1051PubMedCrossRef

73.

Crockett DJ, Ahmed SR, Sowder DR et al (2014) Velopharyngeal dysfunction in children with Prader-Willi syndrome after adenotonsillectomy. Int J Ped Otorhinolaryngology 78:1731–1734CrossRef

74.

Qaseem A, Holty JE, Owens DK, Dallas P, Starkey M, Shekelle P, For the Clinical Guidelines Committee of the American College of Physicians (2013) Management of obstructive sleep Apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 159(7):471–483

75.

Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A (2007) Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A 143A(13):1456–1461PubMedCrossRef

76.

Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14(1):10–26PubMedCrossRef

77.

Butler MG, Sturich J, Lee J, Myers SE, Whitman BY, Gold JA, Kimonis V, Scheimann A, Terrazas N, Driscoll DJ (2011) Growth standards of infants with Prader-Willi syndrome. Pediatrics 127(4):687–695PubMedCentralPubMedCrossRef

78.

Butler MG, Lee J, Manzardo AM, Gold JA, Miller JL, Kimonis V, Driscoll DJ (2015) Growth charts for non-growth hormone treated Prader-Willi syndrome. Pediatrics 135(1):e126–e135PubMedPubMedCentralCrossRef

79.

Grugni G, Crinò A, Pagani S, Meazza C, Buzi F, De Toni T, Gargantini L, Pilotta A, Pozzan GB, Radetti G, Ragusa L, Salvatoni A, Sartorio A (2011) Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome. J Pediatr Endocrinol Metab 24(7–8):477–481PubMed

80.

Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB (2010) Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab 95:1131–1136PubMedCentralPubMedCrossRef

81.

Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M (1996) Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 9(3):393–400PubMedCrossRef

82.

Eiholzer U, l’Allemand D (2000) Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 53(4):185–192

83.

Bakker NE, Kuppens RJ, Siemensma EP et al (2013) Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 98(10):4013–4022PubMedCrossRef

84.

Nakamura Y, Murakami N, Iida T, Asano S, Ozeki S, Nagai T (2014) Growth hormone treatment for osteoporosis in patients with scoliosis of Prader-Willi syndrome. J Orthop Sci 19:877–882PubMedCrossRef

85.

Oto Y, Tanaka Y, Abe Y, Obata K, Tsuchiya T, Yoshino A, Murakami N, Nagai T (2014) Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A 164A(3):671–675PubMedCrossRef

86.

Coupaye M, Lorenzini F, Llore-Linares C et al (2013) Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab 98:E328–E335PubMedCrossRef

87.

Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, Donnelly JE (2013) Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm IGF Res 23(3):81–87PubMedCentralPubMedCrossRef

88.

Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, Vismara L, Rizzo G, Grugni G (2014) Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 99:1816–1824PubMedCrossRef

89.

Marzullo P, Marcassa C, Campini R, Eleuteri E, Minocci A, Priano L, Temporelli P, Sartorio A, Vettor R, Liuzzi A, Grugni G (2005) The Impact of growth hormone/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab 90:5639–5646PubMedCrossRef

90.

Marzullo P, Marcassa C, Minocci A, Campini R, Eleuteri E, Alessandro Gondoni L, Aimaretti G, Sartorio A, Scacchi M, Grugni G (2015) Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. doi:10.1210/jc2015-1063 PubMed

91.

Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB (2007) Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 143A(5):443–448PubMedCrossRef

92.

Festen DA, Wevers M, Lindgren AC, Böhm B, Otten BJ, Wit JM et al (2008) Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol 68:919–925CrossRef

93.

Siemensma EP, de Lindvanwijngaarder RF, Festen DA et al (2012) Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 97(7):2307–2314PubMedCrossRef

94.

Höybye C, Thorén M, Böhm B (2005) Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J Intellect Disabil Res 49:245–252PubMedCrossRef

95.

Böhm B, Ritzén EM, Lindgren AC (2014) Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi Syndrome. Acta Paediatric 104:59–67CrossRef

96.

Deal CL, Tony M, Höybye C et al (2013) Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 98:E1072–E1087PubMedCentralPubMedCrossRef

97.

Feigerlova E, Diene G, Oliver I, Gennero I, Salles JP, Arnaud C, Tauber M (2010) Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. J Clin Endocrinol Metab 95(10):4600–4608PubMedCrossRef

98.

Nagai T, Obata K, Ogata T, Murakami N, Katada Y, Yoshino A, Sakazume S, Tomita Y, Sakuta R, Niikawa N (2006) Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome. Am J Med Genet A 140:1623–1627PubMedCrossRef

99.

de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Hokken-Koelega AC (2008) Scoliosis in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body mass and genotype. Arch Dis Child 93:1012–1016PubMedCrossRef

100.

Odent T, Accadbled F, Koureas G, Cournot M, Moine A, Diene G, Molinas C, Pinto G, Tauber M, Gomes B, de Gauzy JS, Glorion C (2008) Scoliosis in patients with Prader-Willi-Syndrome. Pediatrics 122(2):e499–e503PubMedCrossRef

101.

Diene G, de Gauzy JS, Tauber M (2008) Is scoliosis an issue for giving growth hormone to children with Prader-Willi syndrome? Arch Dis Childhood 93(12):1004–1006CrossRef

102.

de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC (2009) Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 94(4):1274–1280PubMedCrossRef

103.

Murakami N, Obata K, Abe Y, Oto Y, Kido Y, Itabashi H, Tsuchiya T, Tanaka Y, Yoshino A, Nagai T (2012) Scoliosis in Prader-Willi syndrome: effect of growth hormone therapy and value of paravertebral muscle volume by CT in predicting scoliosis progression. Am J Med Genet A 158A(7):1628–1633PubMedCrossRef

104.

Tauber M, Diene G, Molinas C, Hébert M (2008) Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet Part A 146(7):881–887CrossRef

105.

Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Taffe J, Dykens E (2006) Mortality in Prader-Willi syndrome. Am J Ment Retard 111(3):193–198PubMedCentralPubMedCrossRef

106.

Van Vliet G, Deal CL, Crock PA, Robitaille Y, Oligny LL (2004) Sudden death in growth hormone–treated children with Prader-Willi syndrome. J Pediatr 144:129–131PubMedCrossRef

107.

Mogul HR, Lee PD, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL (2008) Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab 93(4):1238–1245

108.

Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Hoybye C (2012) Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 41(2):191–199PubMedCrossRef

109.

Sode-Carlsen R et al (2010) One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J Clin Endocrinol Metab 95(11):4943–4950PubMedCrossRef

110.

Sanchez-Ortiga R, Klibanski A, Tritos NA (2012) Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol 77(1):86–93CrossRef

111.

Molitch M, Clemmons D, Malozowski S, Merriam G, Vance M (2011) Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guidelines. J Clin Endocrinol Metab 96(6):1587–1609PubMedCrossRef

112.

Vogels A, Moerman P, Frijns JP, Bogaert GA (2008) Testicular histology in boys with Prader-Willi syndrome: fertile or infertile? J Urol 180:1800–1804

113.

Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC (2012) Testicular failure in boys with Prader-Willi syndrome: longitudinal studies of reproductive hormones. J Clin Endocrinol Metab 97:E452–E459PubMedCrossRef

114.

Radicioni AF, Di Giorgio G, Grugni G, Cuttini M, Losacco V, Anzuini A, Spera S, Marzano C, Lenzi A, Cappa M, Crinó A (2012) Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader-Willi syndrome. Clin Endocrinol (Oxf) 76:72–77CrossRef

115.

Eiholzer U, l’Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Gruters A, Simoni M (2006) Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab 91:892–898

116.

Fillion M, Deal CL, Van Vliet G (2006) Normal minipuberty of infancy in boys with Prader-Willi syndrome. J Pediatr 149:874–876PubMedCrossRef

117.

Hirsch HJ, Eldar-Geva T, Erlichman M, Pollak Y, Gross-Tsur V (2014) Characterization of minipuberty in infants with Prader-Willi syndrome. Horm Res Paediatr 82:230–237PubMedCrossRef

118.

Siemensma EP, van Alfen-van der Velden AA, Otten BJ, Laven JS, Hokken-Koelega AC (2012) Ovarian function and reproductive hormone levels in girls with Prader-Willi syndrome: a longitudinal study. J Clin Endocrinol Metab 97:E1766–E1773PubMedCrossRef

119.

Eldar-Geva T, Hirsch HJ, Rabinowitz R, Benarroch F, Rubinstein O, Gross-Tsur V (2009) Primary ovarian dysfunction contributes to the hypogonadism in women with Prader-Willi Syndrome. Horm Res 72(3):153–159PubMedCrossRef

120.

Eldar-Geva T, Hirsch HJ, Benarroch F, Rubinstein O, Gross-Tsur V (2010) Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur J Endocrinol 162(2):377–384PubMedCrossRef

121.

Akefeldt A, Tornhage CJ, Gillberg C (1999) A woman with Prader-Willi syndrome gives birth to a healthy baby girl. Dev Med Child Neurol 41:789–790PubMedCrossRef

122.

Schulze A, Mogensen H, Hamborg-Petersen B, Graem N, Ostergaard JR, Brondum-Nielsen K (2001) Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. Acta Paediatr 90:455–459PubMedCrossRef

123.

Schmidt H, Schwarz PS (2001) Premature adrenarche, increased growth velocity and accelerated bone age in male patients with Prader-Labhart-Willi syndrome. Eur J Pediatr 160:69–70PubMedCrossRef

124.

125.

Siemensma EP, Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC (2011) Pubarche and serum dehydroepiandrosterone sulphate levels in children with Prader-Willi syndrome. Clin Endocrinol (Oxf) 75:83–89CrossRef

126.

Butler MG, Haber L, Mernaugh R, Carlson MG, Price R, Feurer ID (2001) Decreased bone mineral density in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet 103:216–222PubMedCrossRef

127.

Vestergaard P, Kristensen K, Bruun JM, Østergaard JR, Heickendorff L, Mosekilde L, Richelsen B (2004) Reduced bone mineral density and increased bone turnover in prader-willi syndrome compared with controls matched for sex and body mass index—a cross-sectional study. J Pediatr 144(5):614–619PubMedCrossRef

128.

Bakker NE, Wolffenbuttel KP, Looijenga LH, Hokken-Koelega AC (2015) Testes in enfants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol 193:291–298PubMedCrossRef

129.

McCandless SE, Committee in Genetics (2011) Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics 127(1):195–204

130.

Young J (2012) Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 97:707–718PubMedCrossRef

131.

Zitzmann M, Nieschlag E (2000) Hormone substitution in male hypogonadism. Mol Cell Endocrinol 161:73–88PubMedCrossRef

132.

Tauber M, Barbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A, Rochiccioli P (2000) Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. Horm Res 53(6):279–287PubMedCrossRef

133.

Butler M, Theodoro M, Skouse JD (2007) Thyroid function studies in Prader-Willi syndrome. Am J Med Genet Part A 143A:488–492PubMedCrossRef

134.

Vaiani E, Herzovich V, ChalerE Chertkoff L, Rivarola MA, Torrado M, Belgorosky A (2010) Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. Clin Endocrinol (Oxf) 73:546–550

135.

Sharkia M, Michaud S, Berthier MT, Giguère Y, Stewart L, Deladoëy J, Deal C, Van Vliet G, Chanoine JP (2013) Thyroid function from birth to adolescence in Prader-Willi syndrome. J Pediatr 163(3):800–805PubMedCrossRef

136.

Lind van Wijngaarden RF, Otten BJ, Festen DA, Joosten KF, de Jong FH, Sweep FC, Hokken-Koelega AC (2008) High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 93:1649–1654PubMedCrossRef

137.

Grugni G, Beccaria L, Corrias A, Crino A, Cappa M, De Medici C, Candia SD, Gargantini L, Ragusa L, Salvatoni A et al (2013) Central adrenal insufficiency in young adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 79:371–378CrossRef

138.

Corrias A, Grugni G, Crino A, Di Candia S, Chiabotto P, Cogliardi A, Chiumello G, De Medici C, Spera S, Gargantini L et al (2012) Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) 76:843–850CrossRef

139.

Connell NA, Paterson WF, Wallace AM, Donaldson MD (2010) Adrenal function and mortality in children and adolescents with Prader-Willi syndrome attending a single centre from 1991–2009. Clin Endocrinol (Oxf) 73:686–688CrossRef

140.

Nyunt O, Cotterill AM, Archbold SM, Wu JY, Leong GM, Verge CF, Crock PA, Ambler GR, Hofman P, Harris M (2010) Normal cortisol response on low-dose synacthen (1 microg) test in children with Prader-Willi syndrome. J Clin Endocrinol Metab 95:E464–E467PubMedCrossRef

141.

Farholt S, Sode-Carlsen R, Christiansen JS, Ostergaard JR, Hoybye C (2011) Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 96:E173–E180PubMedCrossRef

142.

Blum WF, Deal C, Zimmermann AG, Shavrikova EP, Child CJ, Quigley CA, Drop SL, Cutler GB Jr, Rosenfeld RG (2013) Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with idiopathic isolated GH deficiency. Eur J Endocrinol 170:13–21PubMedCrossRef

143.

Melmet S, Jameson JL (2013) Disorders of the anterior pituitary and hypothalamus. In: Jameson JL (ed) Harrison’s Endocrinology, 3rd edn. McGraw-Hill, New York, pp 16–49

144.

Vaitukaitis JL, Dale SL, Melby JC (1969) Role of ACTH in the secretion of dehydroepiandrosterone and its sulfate ester in man. J Clin Endocrinol Metab 29:1443–1447PubMedCrossRef

145.

Rosenfeld RS, Hellman L, Gallagher TF (1972) Metabolism and interconversion of dehydroepiandrosterone and dehydroepiandrosterone sulfate. J Clin Endocrinol Metab 35:187–193PubMedCrossRef

146.

Voutilainen R, Jääskeläinen J (2015) Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 145:226–236PubMedCrossRef

Title: Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings
Authors: M. A. Angulo
M. G. Butler
M. E. Cataletto
Publication date: 01-12-2015
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 12/2015
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0312-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings

Abstract

Introduction

Methods

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2015

The endocrine disruptor cadmium alters human osteoblast-like Saos-2 cells homeostasis in vitro by alteration of Wnt/β-catenin pathway and activation of caspases

Brigida del Rio, “La Barbuda de Peñaranda” (1590): Juan Sánchez Cotán (1560–1627)

Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case–control study

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance

Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA)

Assessment of human lymphocyte proliferation associated with metabolic syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page